Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China
CONCLUSIONS: Sin+Chemo is a cost-effective first-line treatment option for advanced HER2-negative GC/GEJC in China.CLINICAL TRIAL REGISTRATION: ORIENT-16, www.clinicaltrials.gov, identifier is NCT03745170.PMID:38594905 | DOI:10.1080/14737167.2024.2341859 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - April 10, 2024 Category: Health Management Authors: Wei Li Li Wan Source Type: research
Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
British Journal of Cancer, Published online: 10 April 2024; doi:10.1038/s41416-024-02665-zNeratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models (Source: British Journal of Cancer)
Source: British Journal of Cancer - April 10, 2024 Category: Cancer & Oncology Authors: Maryam Arshad Abul Azad Phoebe Yuen Ka Chan Vasanthy Vigneswara Katharina Feldinger Siti Norasikin Mohd Nafi Eloise Laporte-Maguire Carmela De Santo Jianmin Zuo Abeer M. Shaaban Anthony Kong Source Type: research
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
CONCLUSION: Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.PMID:38592638 | DOI:10.1007/s12094-024-03472-x (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Lidan Chang Dandan Liu Xuyan Zhao Luyao Dai Xueting Ren Qian Hao Peinan Liu Hao Wu Xiaobin Ma Huafeng Kang Source Type: research
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
CONCLUSION: Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.PMID:38592638 | DOI:10.1007/s12094-024-03472-x (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Lidan Chang Dandan Liu Xuyan Zhao Luyao Dai Xueting Ren Qian Hao Peinan Liu Hao Wu Xiaobin Ma Huafeng Kang Source Type: research
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
CONCLUSION: These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.PMID:38594618 | DOI:10.1186/s11658-024-00555-z (Source: Mol Biol Cell)
Source: Mol Biol Cell - April 9, 2024 Category: Molecular Biology Authors: Weisong Li Chao Zheng Xi Xu Yujie Xia Kai Zhang Ao Huang Xinyu Zhang Yong Zheng Guofang Chen Shuyong Zhang Source Type: research
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
CONCLUSION: These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.PMID:38594618 | DOI:10.1186/s11658-024-00555-z (Source: Cellular and Molecular Biology Letters)
Source: Cellular and Molecular Biology Letters - April 9, 2024 Category: Biochemistry Authors: Weisong Li Chao Zheng Xi Xu Yujie Xia Kai Zhang Ao Huang Xinyu Zhang Yong Zheng Guofang Chen Shuyong Zhang Source Type: research
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
CONCLUSION: Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.PMID:38592638 | DOI:10.1007/s12094-024-03472-x (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Lidan Chang Dandan Liu Xuyan Zhao Luyao Dai Xueting Ren Qian Hao Peinan Liu Hao Wu Xiaobin Ma Huafeng Kang Source Type: research
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+ breast cancer patients: a subgroup analysis based on different high-risk signatures
CONCLUSION: Our findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies.PMID:38592638 | DOI:10.1007/s12094-024-03472-x (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2024 Category: Cancer & Oncology Authors: Lidan Chang Dandan Liu Xuyan Zhao Luyao Dai Xueting Ren Qian Hao Peinan Liu Hao Wu Xiaobin Ma Huafeng Kang Source Type: research
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
CONCLUSION: These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.PMID:38594618 | PMC:PMC11005275 | DOI:10.1186/s11658-024-00555-z (Source: Mol Biol Cell)
Source: Mol Biol Cell - April 9, 2024 Category: Molecular Biology Authors: Weisong Li Chao Zheng Xi Xu Yujie Xia Kai Zhang Ao Huang Xinyu Zhang Yong Zheng Guofang Chen Shuyong Zhang Source Type: research
Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced BRAF-mutant melanoma
CONCLUSION: These findings establish a preclinical foundation for the combined use of an anti-HER2 drug conjugate and a BRAF inhibitor in the treatment of BRAF-mutant cutaneous melanoma.PMID:38594618 | PMC:PMC11005275 | DOI:10.1186/s11658-024-00555-z (Source: Cellular and Molecular Biology Letters)
Source: Cellular and Molecular Biology Letters - April 9, 2024 Category: Biochemistry Authors: Weisong Li Chao Zheng Xi Xu Yujie Xia Kai Zhang Ao Huang Xinyu Zhang Yong Zheng Guofang Chen Shuyong Zhang Source Type: research
Can neoadjuvant systemic therapy provide additional benefits for T1 HER2+  breast cancer patients: a subgroup analysis based on different high-risk signatures
ConclusionOur findings suggest that NAST does not provide additional benefit to patients with T1 HER2+ breast cancer, even in the presence of lymph node metastasis, T1c, or hormone receptor negativity. This study facilitates the implementation of individualized management strategies. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - April 9, 2024 Category: Cancer & Oncology Source Type: research
